MAPLIGHT THERAPEUTICS INC (MPLT) Fundamental Analysis & Valuation

NASDAQ:MPLT • US56565P1030

Current stock price

21.17 USD
+0.34 (+1.63%)
At close:
21.17 USD
0 (0%)
After Hours:

This MPLT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MPLT Profitability Analysis

1.1 Basic Checks

  • In the past year MPLT has reported negative net income.
  • In the past year MPLT has reported a negative cash flow from operations.
MPLT Yearly Net Income VS EBIT VS OCF VS FCFMPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • MPLT has a Return On Assets of -154.27%. This is amonst the worse of the industry: MPLT underperforms 84.72% of its industry peers.
  • MPLT's Return On Equity of -203.52% is on the low side compared to the rest of the industry. MPLT is outperformed by 69.25% of its industry peers.
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROIC N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MPLT Yearly ROA, ROE, ROICMPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MPLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MPLT Yearly Profit, Operating, Gross MarginsMPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MPLT Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for MPLT remains at a similar level compared to 1 year ago.
  • MPLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MPLT Yearly Shares OutstandingMPLT Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MPLT Yearly Total Debt VS Total AssetsMPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • MPLT has an Altman-Z score of 19.57. This indicates that MPLT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 19.57, MPLT belongs to the top of the industry, outperforming 88.39% of the companies in the same industry.
  • MPLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.57
ROIC/WACCN/A
WACCN/A
MPLT Yearly LT Debt VS Equity VS FCFMPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • MPLT has a Current Ratio of 4.89. This indicates that MPLT is financially healthy and has no problem in meeting its short term obligations.
  • MPLT has a Current ratio (4.89) which is comparable to the rest of the industry.
  • A Quick Ratio of 4.89 indicates that MPLT has no problem at all paying its short term obligations.
  • MPLT has a Quick ratio of 4.89. This is comparable to the rest of the industry: MPLT outperforms 55.71% of its industry peers.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.89
MPLT Yearly Current Assets VS Current LiabilitesMPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MPLT Growth Analysis

3.1 Past

  • The earnings per share for MPLT have decreased strongly by -39.26% in the last year.
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MPLT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -27.50% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-246.02%
EPS Next 2Y-41.82%
EPS Next 3Y-27.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MPLT Yearly EPS VS EstimatesMPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MPLT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MPLT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MPLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MPLT Price Earnings VS Forward Price EarningsMPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MPLT Per share dataMPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • MPLT's earnings are expected to decrease with -27.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.82%
EPS Next 3Y-27.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MPLT Dividend Analysis

5.1 Amount

  • MPLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MPLT Fundamentals: All Metrics, Ratios and Statistics

MAPLIGHT THERAPEUTICS INC

NASDAQ:MPLT (4/2/2026, 8:00:01 PM)

After market: 21.17 0 (0%)

21.17

+0.34 (+1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners47.87%
Inst Owner ChangeN/A
Ins Owners3.33%
Ins Owner Change50.17%
Market Cap960.48M
Revenue(TTM)N/A
Net Income(TTM)-129.76M
Analysts88
Price Target32.44 (53.24%)
Short Float %5.99%
Short Ratio6.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.58%
PT rev (3m)2.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 15.06
P/tB 15.06
EV/EBITDA N/A
EPS(TTM)-3.13
EYN/A
EPS(NY)-3.77
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.27%
ROE -203.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.6%
ROA(5y)N/A
ROE(3y)-96.44%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.89
Altman-Z 19.57
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)107.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.63%
EPS Next Y-246.02%
EPS Next 2Y-41.82%
EPS Next 3Y-27.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.74%
EBIT Next 3Y-39.22%
EBIT Next 5YN/A
FCF growth 1Y-51.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.55%
OCF growth 3YN/A
OCF growth 5YN/A

MAPLIGHT THERAPEUTICS INC / MPLT Fundamental Analysis FAQ

What is the fundamental rating for MPLT stock?

ChartMill assigns a fundamental rating of 2 / 10 to MPLT.


Can you provide the valuation status for MAPLIGHT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MAPLIGHT THERAPEUTICS INC (MPLT). This can be considered as Overvalued.


Can you provide the profitability details for MAPLIGHT THERAPEUTICS INC?

MAPLIGHT THERAPEUTICS INC (MPLT) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MPLT stock?

The Earnings per Share (EPS) of MAPLIGHT THERAPEUTICS INC (MPLT) is expected to decline by -246.02% in the next year.